Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the BRAF V600E mutation in multiple myeloma.

Cancer discovery - 1 Aug 2013

Andrulis Mindaugas, Lehners Nicola, Capper David, Penzel Roland, Heining Christoph, Huellein Jennifer, Zenz Thorsten, von Deimling Andreas, Schirmacher Peter, Ho Anthony D, Goldschmidt Hartmut, Neben Kai, Raab Marc S

Abstract excerpt

In multiple myeloma, there has been little progress in the specific therapeutic targeting of oncogenic mutations. Whole-genome sequencing data have recently revealed that a subset of patients carry an activating mutation (V600E) in the BRAF kinase. To uncover the clinical relevance of this mutation in multiple myeloma, we correlated the mutation status in primary tumor samples from 379 patients with myeloma with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clonal Evolution
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Multiple Myeloma

Share to Plasma Cells

Share to Sequence Analysis

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 23612012
DOI: 10.1158/2159-8290.CD-13-0014

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the BRAF V600E mutation in multiple myeloma.PMID 23612012Read ↗

Targeting BRAF in multiple myeloma.Semantic proximity Read ↗

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.Semantic proximity Read ↗

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.Semantic proximity Read ↗

Initial genome sequencing and analysis of multiple myeloma.Semantic proximity Read ↗

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.Semantic proximity Read ↗

Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients.Semantic proximity Read ↗

Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations.Semantic proximity Read ↗

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.Semantic proximity Read ↗

Novel genomic findings in multiple myeloma identified through routine diagnostic sequencingSemantic proximity Read ↗

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease ProgressionSemantic proximity Read ↗

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.Semantic proximity Read ↗

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.